Prestige Consumer Healthcare (NYSE:PBH) Stock Rating Reaffirmed by Canaccord Genuity Group

Prestige Consumer Healthcare (NYSE:PBH)‘s stock had its “buy” rating reissued by stock analysts at Canaccord Genuity Group in a report released on Tuesday, Benzinga reports. They currently have a $80.00 price target on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 23.59% from the stock’s current price.

Several other analysts have also commented on the stock. StockNews.com lowered shares of Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. TheStreet raised shares of Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research report on Monday, February 12th. Finally, DA Davidson reissued a “neutral” rating and set a $65.00 price target on shares of Prestige Consumer Healthcare in a research report on Thursday, May 16th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $91.25.

Prestige Consumer Healthcare Stock Down 0.5 %

NYSE:PBH opened at $64.73 on Tuesday. Prestige Consumer Healthcare has a 1-year low of $55.96 and a 1-year high of $75.31. The company has a 50-day moving average of $70.10 and a 200 day moving average of $65.38. The firm has a market cap of $3.23 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 1.83 and a beta of 0.53. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 2.02.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Tuesday, May 14th. The company reported $1.02 earnings per share for the quarter, missing analysts’ consensus estimates of $1.14 by ($0.12). The business had revenue of $277.00 million during the quarter, compared to analysts’ expectations of $287.42 million. Prestige Consumer Healthcare had a return on equity of 13.48% and a net margin of 18.60%. The firm’s revenue was down 3.1% compared to the same quarter last year. During the same period last year, the company earned $1.07 earnings per share. As a group, research analysts anticipate that Prestige Consumer Healthcare will post 4.41 EPS for the current fiscal year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently bought and sold shares of PBH. Ariel Investments LLC increased its holdings in Prestige Consumer Healthcare by 173.8% in the 3rd quarter. Ariel Investments LLC now owns 2,534,786 shares of the company’s stock worth $144,964,000 after buying an additional 1,609,044 shares during the period. Congress Asset Management Co. MA grew its stake in shares of Prestige Consumer Healthcare by 596.2% during the 4th quarter. Congress Asset Management Co. MA now owns 679,256 shares of the company’s stock worth $41,584,000 after purchasing an additional 581,685 shares during the period. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare during the 4th quarter worth approximately $27,739,000. Norden Group LLC lifted its position in shares of Prestige Consumer Healthcare by 1,593.7% during the 1st quarter. Norden Group LLC now owns 118,968 shares of the company’s stock valued at $8,632,000 after buying an additional 111,944 shares in the last quarter. Finally, UBS Group AG lifted its position in shares of Prestige Consumer Healthcare by 377.6% during the 4th quarter. UBS Group AG now owns 131,382 shares of the company’s stock valued at $8,043,000 after buying an additional 103,872 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.